Tag: drug injury
-
Elmiron Pigmentary Maculopathy Risk Warning Issued by Janssen and Health Canada in December 2020
New Medical Article Describes How to Identify, Image, and Diagnose Pigmentary Maculopathy Caused by Elmiron Use (Posted by Tom Lamb at Drug Injury Watch) On December 15, 2020 a Dear Healthcare Professional…
-
Novartis Update on Patients Suffering from Retinal Vasculitis and/or Retinal Vascular Occlusion After Beovu Injections
November 2020 Report: Beovu Eye Side Effects Risks Higher for Beovu Patients with Prior Intraocular Inflammation and/or Vascular Occlusion (Posted by Tom Lamb at DrugInjuryWatch.com) We have known since early 2020 that…
-
Gilenya Safety Alert November 2020: Cases of Acute Liver Failure Requiring Liver Transplant
European Medicines Agency (EMA) and Novartis Issue Dear Doctor Letter About Gilenya Label Change (Posted by Tom Lamb at DrugInjuryWatch.com) A recent periodic review of Gilenya safety data by the European Medicines…
-
Beovu Lawsuits Filed Against Novartis for Patients Who Have Suffered Vision Loss Side Effects
Beovu Legal Cases Involve Retinal Artery Occlusion, Retinal Vasculitis, Intraocular Inflammation, Other Eye Problems (Posted by Tom Lamb at DrugInjuryWatch.com) Beovu (brolucizumab) is prescribed for the treatment of neovascular (wet) age-related macular…
-
Picato Recalls Continue with Canada and Denmark Being Most Recent, All Due to Risk of Skin Cancer
A Global Phase-out of Picato Sales by LEO Pharma Inc. Due to this Picato Safety Finding Expected by End of 2020 (Posted by Tom Lamb at DrugInjuryWatch.com) But first, we get…
-
Drug Safety Issue for Stelara: Severe Cardiovascular Events Soon After Initiation of Stelara Treatment
Stelara-Associated Acute Coronary Syndrome, Stroke, and Unstable Angina Seen in Recent Stelara French Medical Study (Posted by Tom Lamb at DrugInjuryWatch.com) Stelara (ustekinumab) was approved by the FDA in 2009, initially for…
-
Ocaliva FDA Adverse Events Reports for Hepatobiliary System Cases: An Analysis as of October 2020
Lack of Warnings in Current Ocaliva Drug Label for Some Serious Side Effects Involving Liver, Gallbladder, Bile Ducts (Posted by Tom Lamb at DrugInjuryWatch.com) We are still wondering how the current FDA…
-
Potential Ocaliva – Liver Disorder Safety Signal Being Investigated by FDA as Side Effects Risk
October 2020 News Report Reveals "New" Ocaliva Liver Safety Issue, Which Had Been Under the Radar Previously (Posted by Tom Lamb at DrugInjuryWatch.com) Ocaliva (obeticholic acid) was approved by the FDA in…